Skipping to Phase III

With a Special Protocol Assessment from FDA in hand, Therion Biologics Corp. believes it has moved into the front ranks of cancer vaccine companies and ahead of others using pox viruses as vectors. The SPA allows Therion to take its PanVac-VF for pancreatic cancer straight into Phase III studies, having completed only Phase I testing with the vaccine.

According to President and CEO Mark Leuchtenberger, the SPA means that the company